Thalassemia Treatment Market Research Report - Global Forecast till 2027

Thalassemia Treatment Market: Information by Type (Alpha-thalassemia, Beta Thalassemia), Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplants), End User (Hospitals and Clinics, Diagnostic Laboratories and others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/7123-HCR | December, 2022 | Region : Global

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Research Methodology for Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. Regulatory Framework

6. GLOBAL THALASSEMIA TREATMENT MARKET, BY TYPE

6.1. Overview

6.2. Alpha-thalassemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Beta Thalassemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Blood Transfusions

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Iron Chelation Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Folic Acid Supplements

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Gene therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL THALASSEMIA TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Diagnostic laboratories

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL THALASSEMIA TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

10.1.3. Market Share Analysis

10.1.4. Major Growth Strategy in the Global Thalassemia Treatment Market

10.1.5. Competitive Benchmarking

10.1.6. Leading Player in terms of Number of Developments in Global Thalassemia Treatment Market

10.1.7. Key Developments & Growth Strategies

10.1.7.1. Product Launch

10.1.7.2. Merger & Acquisition

10.1.7.3. Joint Ventures

10.1.8. Major Players Financial Matrix

10.1.8.1. Sales & Operating Income 2018

10.1.9. Major Players R&D Expenditure 2018

11. COMPANY PROFILES

11.1. Novartis AG

11.1.1. Company Overview

11.1.2. PRODUCT Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Blueird Bio, Inc.

11.2.1. Company Overview

11.2.2. PRODUCT Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Kiadis Pharma

11.3.1. Company Overview

11.3.2. PRODUCT Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. CELGENE CORPORATION

11.4.1. Company Overview

11.4.2. PRODUCT Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Sangamo Therapeutics

11.5.1. Company Overview

11.5.2. PRODUCT Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Acceleron Pharma, Inc.

11.6.1. Company Overview

11.6.2. PRODUCT Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Gamida Cell.

11.7.1. Company Overview

11.7.2. PRODUCT Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Aspen Medical Products

11.8.1. Company Overview

11.8.2. PRODUCT Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Others

12. APPENDIX

12.1. References

12.2. Related Reports

NOTE:

This table of content is tentative and subject to change as the research progresses.

• In section 10, only top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.

• Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources

LIST OF TABLES

TABLE 1 GLOBAL THALASSEMIA TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL THALASSEMIA TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL THALASSEMIA TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 8 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 11 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 12 US: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 14 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 CANADA: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 17 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 20 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 23 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 26 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 29 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 32 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL THALASSEMIA TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL THALASSEMIA TREATMENT MARKET

FIGURE 4 GLOBAL THALASSEMIA TREATMENT MARKET SHARE, BY TYPE, 2020(%)

FIGURE 5 GLOBAL THALASSEMIA TREATMENT MARKET SHARE, BY TREATMENT, 2020(%)

FIGURE 6 GLOBAL THALASSEMIA TREATMENT MARKET SHARE, BY END USER, 2020(%)

FIGURE 7 GLOBAL THALASSEMIA TREATMENT MARKET SHARE, BY REGION, 2020(%)

FIGURE 8 AMERICAS: THALASSEMIA TREATMENT MARKET SHARE BY REGION, 2020(%)

FIGURE 9 NORTH AMERICA: THALASSEMIA TREATMENT MARKET SHARE, BY COUNTRY, 2020(%)

FIGURE 10 EUROPE: THALASSEMIA TREATMENT MARKET SHARE, BY REGION, 2020(%)

FIGURE 11 WESTERN EUROPE: THALASSEMIA TREATMENT MARKET SHARE, BY COUNTRY, 2020(%)

FIGURE 12 ASIA-PACIFIC: THALASSEMIA TREATMENT MARKET SHARE, BY REGION, 2020(%)

FIGURE 13 MIDDLE EAST & AFRICA: THALASSEMIA TREATMENT MARKET SHARE, BY COUNTRY, 2020(%)

FIGURE 14 GLOBAL THALASSEMIA TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020(%)

FIGURE 15 NOVARTIS AG: KEY FINANCIALS

FIGURE 16 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 17 NOVARTIS AG: REGIONAL REVENUE

FIGURE 18 BLUEBIRD BIO, INC.: KEY FINANCIALS

FIGURE 19 BLUEBIRD BIO, INC.: SEGMENTAL REVENUE

FIGURE 20 BLUEBIRD BIO, INC.: REGIONAL REVENUE

FIGURE 21 KIADIS PHARMA: KEY FINANCIALS

FIGURE 22 KIADIS PHARMA: SEGMENTAL REVENUE

FIGURE 23 KIADIS PHARMA: REGIONAL REVENUE

FIGURE 24 CELGENE CORPORATION: KEY FINANCIALS

FIGURE 25 CELGENE CORPORATION: SEGMENTAL REVENUE

FIGURE 26 CELGENE CORPORATION: REGIONAL REVENUE

FIGURE 27 SANGAMO THERAPEUTICS: KEY FINANCIALS

FIGURE 28 SANGAMO THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 29 SANGAMO THERAPEUTICS: REGIONAL REVENUE

FIGURE 30 ACCELERON PHARMA, INC.: KEY FINANCIALS

FIGURE 31 ACCELERON PHARMA, INC.: SEGMENTAL REVENUE

FIGURE 32 ACCELERON PHARMA, INC.: REGIONAL REVENUE

FIGURE 33 GAMIDA CELL: KEY FINANCIALS

FIGURE 34 GAMIDA CELL: SEGMENTAL REVENUE

FIGURE 35 GAMIDA CELL: REGIONAL REVENUE




This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.